EAE116, NCT05147493 / 2021-004895-32: A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment |
|
|
| Not yet recruiting | 2 | 51 | Europe | Isatuximab, Bortezomib, Cyclophosphamide, Dexamethasone, Lenalidomide | Hellenic Society of Hematology, Sanofi | Multiple Myeloma, Renal Impairment, Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases | 12/24 | 02/25 | | |
